Sidebar
This is an old revision of the document!
Pharmacovigilance evidence investigation Workgroup (used to be Knowledge Base / LAERTES)
Objective: The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. The WG's first contribution to OHDSI will be LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) – a system that integrates numerous sources of evidence useful for investigating the association of drugs and health into a single system. The system will extend the OHDSI Standard Vocabulary and provide for summary and drill down evidence review use cases. The first staging release of LAERTES occurred last year and is reported in https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3.
Project Lead: Richard D. Boyce, PhD
Project Co-Lead: Erica Voss, MPH
Members:
See Members List but note that active membership is completely voluntary and open.
Start Date: 6/10/2014
Repository: https://github.com/OHDSI/KnowledgeBase
WG Minutes: WG Minutes
WG Agendas: WG Agendas
Publications: Boyce, RD., Voss, E., Huser, V., Evans, L., Reich, C., Duke, JD., Tatonetti, NP., Lorberbaum, T., Dumontier, M., Hauben, M., Wallberg, M., Peng, L., Dempster, S., He, O., Sena, A., Koutkias, V., Natsiavas, P., Ryan, P. (Knowledge Base workgroup of the Observational Health Data Sciences and Informatics (OHDSI) collaborative). Large-scale adverse effects related to treatment evidence standardization (LAERTES): an open scalable system for linking pharmacovigilance evidence sources with clinical data. J Biomed Semantics. 2017 Mar 7;8(1):11. doi: 10.1186/s13326-017-0115-3. Available at: https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3. PubMed PMID: 28270198; PubMed Central PMCID: PMC5341176.
E.A. Voss, R.D. Boyce, P.B. Ryan, J. van der Lei, P.R. Rijnbeek, M.J. Schuemie, Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions, Journal of Biomedical Informatics, Available online 16 December 2016, ISSN 1532-0464, http://dx.doi.org/10.1016/j.jbi.2016.12.005.
Boyce. RD., Ryan. PB., Noren. N., et al., Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Safety. 2014. Volume 37, Issue 8 (2014), Page 557-567. DOI: 10.1007/s40264-014-0189-0, PubMed PMID: 24985530. PMCID: PMC4134480. http://link.springer.com/article/10.1007%2Fs40264-014-0189-0
Meetings (Telecon Info)
Schedule: - All team call once per month on the 4th Wednesday of each month at 9-10 Eastern. NOTE: no call in June. Back on schedule starting 7/26/17 - Touch point call on the 2nd Wednesday of each month 9-10 Eastern starting on 7/12/17
Please join my meeting from your computer, tablet or smartphone. https://global.gotomeeting.com/join/530277469
You can also dial in using your phone. United States: +1 (224) 501-3217
Access Code: 530-277-469
More phone numbers Canada: +1 (647) 497-9350 France: +33 170 950 594 Netherlands: +31 207 941 377 Sweden: +46 853 527 836 Switzerland: +41 225 4599 78 United Kingdom: +44 330 221 0088
Discussions
Search for “LAERTES” on http://forums.ohdsi.org/
GitHub Issues
Members List (add or delete your name if you see an omission or error)
Richard D. Boyce, University of Pittsburgh, Pittsburgh, PA, rdb20@pitt.edu
Erica A. Voss, Janssen Research & Development, LLC, Titusville, NJ, EVoss3@its.jnj.com
Vojtech Huser, National Institutes of Health, Bethesda, MD, vojtech.huser@nih.gov
Lee Evans, LTS Computing LLC, West Chester, PA, levans@ltscomputingllc.com
Christian Reich, QuintilesIMS, Burlington MA, reich@ohdsi.org
Jon D. Duke, Georgia Tech Research Institute, Atlanta, GA, Jon.Duke@gatech.edu
Nicholas P. Tatonetti, Herbert Irving Assistant Professor of Biomedical Informatics, Columbia University, New York, NY, nick.tatonetti@columbia.edu
Tal Lorberbaum, Columbia University, New York, NY, tal.lorberbaum@columbia.edu
Michel Dumontier, Stanford University, Stanford, CA, michel.dumontier@gmail.com
Manfred Hauben, MD. MPH, Pfizer Inc, New York University Medical Center, New York, NY, manfred.hauben@pfizer.com
Magnus Wallberg, Uppsala Monitoring Centre, Uppsala, Sweden, Magnus.Wallberg@who-umc.org
Lili Peng, AstraZeneca R&D, Boston , MA, Lili.Peng@astrazeneca.com
Sara Dempster, AstraZeneca R&D, Boston , MA, sara.dempster@astrazeneca.com
Yongqun He, University of Michigan Medical School, Ann Arbor, Michigan, yongqunh@med.umich.edu
Anthony G. Sena, Janssen Research & Development, LLC, Titusville, NJ, asena5@its.jnj.com
Vassilis Koutkias, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, vkoutkias@certh.gr
Pantelis Natsiavas, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, pnatsiavas@certh.gr
Patrick B. Ryan, Janssen Research & Development, LLC, Titusville, NJ, ryan@ohdsi.org
